Get the Stockscreener App
17.36
3.45%
-0.62
After Hours:
17.37
0.01
+0.06%
Relay Therapeutics Inc stock is traded at $17.36, with a volume of 1.70M.
It is down -3.45% in the last 24 hours and down -8.00% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$17.98
Open:
$17.84
24h Volume:
1.70M
Relative Volume:
0.60
Market Cap:
$3.80B
Revenue:
$10.68M
Net Income/Loss:
$-272.71M
P/E Ratio:
-11.09
EPS:
-1.565
Net Cash Flow:
$-213.38M
1W Performance:
-7.36%
1M Performance:
-8.00%
6M Performance:
+13.76%
1Y Performance:
+176.87%
1-Day Range:
$17.27
$17.93
1-Week Range:
$16.87
$18.54
52-Week Range:
$5.85
$21.27
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
17.36 | 3.80B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-26 | Initiated | Canaccord Genuity | Buy |
| Jul-08-26 | Initiated | JP Morgan | Overweight |
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Form 4 Relay Therapeutics Inc For: 8 October By Investing.com - Investing.com Canada
Relay Therapeutics CFO Catinazzo sells $329k in shares - Investing.com
Relay Therapeutics CEO Sanjiv Patel sells $872,401 company stock - Investing.com
CEO sells 48,199 shares under a trading plan at Relay Therapeutics (RLAY). - Stock Titan
Under a trading plan, Relay Therapeutics (RLAY) CFO sells 17,511 shares plus 206 more. - Stock Titan
After two share sales, Sanjiv Patel proposes another at Relay Therapeutics (RLAY). - Stock Titan
After two 17,717-share sales, a Relay Therapeutics (RLAY) officer proposes another sale. - Stock Titan
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option - GlobeNewswire Inc.
Relay Therapeutics (Nasdaq:RLAY)Stock Analysis - simplywall.st
Relay Therapeutics CEO Sanjiv Patel sells 48,199 shares for $912,889.06 - Bitget
Relay Therapeutics (RLAY) Insider Sell: President, R&D Donald Be - GuruFocus
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics R&D president sells $161,814 in stock - Investing.com
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com India
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com Canada
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) R&D chief sells stock under 10b5-1 plan - Stock Titan
Relay Therapeutics (RLAY) CFO sells about $335K in stock under preset plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) CEO sells shares under preset trading plan - Stock Titan
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing - Yahoo Finance
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com Canada
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com UK
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - news.futunn.com
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - Yahoo Finance
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - The Motley Fool
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats - Quiver Quantitative
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - finance.yahoo.com
Relay Therapeutics management will join two live online talks this month - Stock Titan
Relay Therapeutics (RLAY) Insider Peter Rahmer Sells 4,508 Shares - GuruFocus
Relay Therapeutics (RLAY) exec sells 4,508 shares under plan - Stock Titan
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each - Kalkine Media
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com Canada
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com UK
Relay Therapeutics (NASDAQ: RLAY) 10% owner SoftBank sells 6M shares - Stock Titan
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m - Investing.com
Relay Therapeutics (NASDAQ: RLAY) officer eyes another stock sale after June trade - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) holder plans sale of up to 6M shares - Stock Titan
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SANJIV PATEL | Director |
Oct 07 '26 |
Proposed Sale |
18.74 |
96,401 |
1,806,555 |
0 |
| THOMAS CATINAZZO | Officer |
Oct 06 '26 |
Proposed Sale |
19.39 |
93,153 |
1,806,237 |
0 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 06 '26 |
Sale |
18.59 |
17,717 |
329,322 |
105,134 |
| Patel Sanjiv | President and CEO |
Sep 08 '26 |
Sale |
18.94 |
48,199 |
912,889 |
519,500 |
| Catinazzo Thomas | Chief Financial Officer |
Sep 08 '26 |
Sale |
18.94 |
17,717 |
335,560 |
122,851 |
| Bergstrom Donald A | President, R&D |
Sep 08 '26 |
Sale |
18.97 |
8,530 |
161,814 |
399,130 |
| PETER RAHMER | Officer |
Aug 26 '26 |
Proposed Sale |
20.57 |
50,000 |
1,028,500 |
0 |
| Rahmer Peter | See remarks |
Aug 26 '26 |
Sale |
20.03 |
4,508 |
90,295 |
223,657 |
| SVF Pauling (Cayman) Ltd | 10% Owner |
Aug 25 '26 |
Sale |
19.40 |
6,000,000 |
116,400,000 |
21,904,963 |
| SVF Pauling (Cayman) Ltd | Stockholder |
Aug 25 '26 |
Proposed Sale |
20.57 |
6,000,000 |
123,420,000 |
0 |
8.07%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):